HomeAI · summaries
Storia in 6 fonti
Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult | Fortune
A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
independent.co.uk
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
- ·
benzinga.com
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks - Novo Nordisk
Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.
